^
Association details:
| Biomarker: | MSI-H/dMMR + TP53 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.
Published date:
05/13/2020
Excerpt:
In a Chinese cohort of MSI-H/dMMR CRCs receiving ICIs, we found that patients with TP53 mutation (6 out of 16) showed a remarkable lower durable clinic benefit (DCB) rate than TP53 wild-type subgroup (100% vs. 33%, P = 0.008). Moreover, TP53 wild-type patients were associated with prolonged progression-free survival (P = 0.02; HR, 0.11) and overall survival (P = 0.0037; HR, 0.04).
DOI:
10.1200/JCO.2020.38.15_suppl.e16014
